NMRA-140 is under clinical development by Neumora Therapeutics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect NMRA-140’s likelihood of approval (LoA) and phase transition for Major Depressive Disorder took place on 12 Sep 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their NMRA-140 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

NMRA-140 overview

NMRA-140 is under development for the treatment of major depressive disorder (MDD) with anhedonia. The drug candidate is a small molecule that acts by targeting kappa-type opioid receptor (KOR). It is administered through oral route.

Neumora Therapeutics overview

Neumora Therapeutics formerly RBNC Therapeutics, is a biotechnology company that uses data science and neuroscience to develop precision medications to treat brain diseases. Neumora Therapeutics is headquartered in Watertown, Massachusetts, the US.

Quick View NMRA-140 LOA Data

Report Segments
  • Innovator
Drug Name
  • NMRA-140
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
Key Developers
  • Sponsor Company: Neumora Therapeutics
  • Originator: Blackthorn Therapeutics
Highest Development Stage
  • Phase II


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.